Pivotal Trials in mHSPC

Talazoparib plus enzalutamide significantly delayed the deterioration of global health status and quality of life in patients with mCRPC in the TALAPRO-2 study.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

A study of 47,387 patients found radical prostatectomy had the lowest long-term risk of severe genitourinary complications after localized prostate cancer treatment compared to combination therapies.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

Frailty assessments, particularly the G8 tool, BMI, and albumin, may identify mHSPC patients at higher risk for severe adverse events with upfront docetaxel, a study suggests.

The EMBARK analysis showed most men regained testosterone after stopping enzalutamide/leuprolide or placebo/leuprolide for prostate cancer with good PSA response, and recovery was common across age groups.